In Ewing sarcoma (ES), circulating tumor cells carry the EWS-FLI1/ERG chimeric transcript, which can be isolated from bone barrow or peripheral blood in 19–43% of patients, and this target has long been thought to be a potential clinical biomarker for ES patients [38, 39]. This evidence concerns the gene FLI1 and neoplasm.